Will New Results on Merck and GSK's HPV Vaccines Ignite Sales Growth? May 10, 2009 | about stocks: GSK / MRK Mike Huckman is CNBC’s Pharmaceutical Reporter covering the drug, biotechnology and medical device industries. Huckman is based at the network’s global headquarters in … [Read more...] about Financial Analysts Judge Merck and Glaxo Sales Growth
FDA
M-Words: Merck, Money, Market Share
Merck and Glaxo Fight for Increased HPV-Vaccine Sales HPV vaccines were a hot topic during the 25th International Papillomavirus Conference, held May 8-14 in Malmö, Sweden. In the weeks leading up to the big event, Glaxo’s PR machine has been touting new Cervarix vs. Gardasil … [Read more...] about M-Words: Merck, Money, Market Share
CDC Reports HPV-Vaccine Health Concerns
HPV Vaccine Safety The safety of the HPV vaccine was studied in 5 clinical trials before it was licensed. There were over 21,000 girls and women ages 9 through 26 in these clinical trials. Since it was licensed, CDC and FDA have been closely monitoring the safety of the … [Read more...] about CDC Reports HPV-Vaccine Health Concerns
Merck Has A History of Producing Contaminated Vaccine Product
Gardasil — The Hidden Truth This weekend, while I was doing some additional research for our next book, Gardasil — The Hidden Truth, I found a previously undisclosed 1987 filmed interview of Merck's chief vaccine researcher and the "Father" of modern childhood vaccines, the late … [Read more...] about Merck Has A History of Producing Contaminated Vaccine Product
‘One Less’ Reason To Talk About Pap Test
Staying on message, while making the numbers sing a happy tune Merck's "One Less" Marketing team is like a well oiled machine. It stays on message no mater what. A key message Merck likes to repete when touting Gardasil is that the vaccine prevents the two strains of HPV that … [Read more...] about ‘One Less’ Reason To Talk About Pap Test